Phase II Clinical Development of New Drugs (ICSA Book Series in Statistics)

(1)
Phase II Clinical Development of New Drugs (ICSA Book Series in Statistics) image
ISBN-10:

9811350744

ISBN-13:

9789811350740

Edition: Softcover reprint of the original 1st ed. 2017
Released: Dec 12, 2018
Publisher: Springer
Format: Paperback, 258 pages

Description:

This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.

Best prices to buy, sell, or rent ISBN 9789811350740




Frequently Asked Questions about Phase II Clinical Development of New Drugs (ICSA Book Series in Statistics)

You can buy the Phase II Clinical Development of New Drugs (ICSA Book Series in Statistics) book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

The price for the book starts from $104.00 on Amazon and is available from 14 sellers at the moment.

If you’re interested in selling back the Phase II Clinical Development of New Drugs (ICSA Book Series in Statistics) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the Phase II Clinical Development of New Drugs (ICSA Book Series in Statistics) book, the best buyback offer comes from and is $ for the book in good condition.

The Phase II Clinical Development of New Drugs (ICSA Book Series in Statistics) book is in very low demand now as the rank for the book is 7,967,347 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.

Not enough insights yet.